Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 8, Pages 797-810
Publisher
Springer Science and Business Media LLC
Online
2019-04-13
DOI
10.1007/s40265-019-01104-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gut-brain axis and the spread of α-synuclein pathology: vagal highway or dead end?
- (2019) David P. Breen et al. MOVEMENT DISORDERS
- The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration
- (2019) Danielle E. Mor et al. MOVEMENT DISORDERS
- The genetics of Parkinson disease
- (2018) Hao Deng et al. AGEING RESEARCH REVIEWS
- Is Parkinson’s disease a lysosomal disorder?
- (2018) Andrés D Klein et al. BRAIN
- Somatic copy number gains of α-synuclein (SNCA) in Parkinson’s disease and multiple system atrophy brains
- (2018) Katya Mokretar et al. BRAIN
- Immunologic treatment of Parkinson's disease
- (2018) Joseph Jankovic Immunotherapy
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
- (2018) S. Pablo Sardi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies
- (2018) Chao Peng et al. NATURE
- LRRK2 kinase in Parkinson's disease
- (2018) Dario R. Alessi et al. SCIENCE
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- (2018) Joseph Jankovic et al. JAMA Neurology
- Progression in the LRRK2-Associated Parkinson Disease Population
- (2018) Rachel Saunders-Pullman et al. JAMA Neurology
- Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
- (2018) Jessika C. Bridi et al. Frontiers in Neuroscience
- Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
- (2018) Veronica Ghiglieri et al. Frontiers in Neurology
- Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
- (2018) Ariadna Recasens et al. Acta Neuropathologica Communications
- β2-adrenoreceptor medications and risk of Parkinson disease
- (2018) Susan Searles Nielsen et al. ANNALS OF NEUROLOGY
- A comprehensive analysis of SNCA -related genetic risk in sporadic parkinson disease
- (2018) Lasse Pihlstrøm et al. ANNALS OF NEUROLOGY
- Selective autophagy as a potential therapeutic target for neurodegenerative disorders
- (2018) Aurora Scrivo et al. LANCET NEUROLOGY
- Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound
- (2018) Kristiana Xhima et al. MOVEMENT DISORDERS
- Gene therapy for neurological disorders: progress and prospects
- (2018) Benjamin E. Deverman et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting prion-like protein spreading in neurodegenerative diseases
- (2018) Liam Chen et al. Neural Regeneration Research
- New Frontiers in Parkinson's Disease: From Genetics to the Clinic
- (2018) Lamya S. Shihabuddin et al. JOURNAL OF NEUROSCIENCE
- Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment
- (2018) Saranna Fanning et al. MOLECULAR CELL
- Pathogenesis-targeted therapeutic strategies in Parkinson's disease
- (2018) Joseph Jankovic MOVEMENT DISORDERS
- The vermiform appendix impacts the risk of developing Parkinson’s disease
- (2018) Bryan A. Killinger et al. Science Translational Medicine
- Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
- (2018) Andreas Weihofen et al. NEUROBIOLOGY OF DISEASE
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- Therapeutic approaches to target alpha-synuclein pathology
- (2017) Patrik Brundin et al. EXPERIMENTAL NEUROLOGY
- A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
- (2017) Jérôme Stirnemann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Parkinson's Disease Is Not Simply a Prion Disorder
- (2017) D. James Surmeier et al. JOURNAL OF NEUROSCIENCE
- Therapies targeting DNA and RNA in Huntington's disease
- (2017) Edward J Wild et al. LANCET NEUROLOGY
- Media hype: Patient and scientific perspectives on misleading medical news
- (2017) Israel Robledo et al. MOVEMENT DISORDERS
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
- (2017) J.A. Obeso et al. MOVEMENT DISORDERS
- T cells from patients with Parkinson’s disease recognize α-synuclein peptides
- (2017) David Sulzer et al. NATURE
- A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
- (2017) Diana Chang et al. NATURE GENETICS
- α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
- (2017) Yvette C Wong et al. NATURE MEDICINE
- Zeroing in on neurodegenerative α-synuclein
- (2017) Katie Kingwell NATURE REVIEWS DRUG DISCOVERY
- Vagotomy and Parkinson disease
- (2017) Bojing Liu et al. NEUROLOGY
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
- (2017) Shuchi Mittal et al. SCIENCE
- Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
- (2017) Anna Migdalska-Richards et al. SYNAPSE
- c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
- (2017) Saurav Brahmachari et al. Journal of Parkinsons Disease
- LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
- (2017) Hien Tran Zhao et al. Molecular Therapy-Nucleic Acids
- Exploring Braak’s Hypothesis of Parkinson’s Disease
- (2017) Carmen D. Rietdijk et al. Frontiers in Neurology
- The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease
- (2017) David I. Finkelstein et al. Acta Neuropathologica Communications
- A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
- (2017) Jess-Karan S. Dhillon et al. PLoS One
- Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
- (2017) Antonio Martin-Bastida et al. Scientific Reports
- Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
- (2016) Morten Gersel Stokholm et al. ANNALS OF NEUROLOGY
- Survival and dementia inGBA-associated Parkinson's disease: The mutation matters
- (2016) Roberto Cilia et al. ANNALS OF NEUROLOGY
- Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease
- (2016) Wolfgang Wrasidlo et al. BRAIN
- New and emerging medical therapies in Parkinson’s disease
- (2016) Mitesh Lotia et al. EXPERT OPINION ON PHARMACOTHERAPY
- Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration
- (2016) Saurav Brahmachari et al. JOURNAL OF CLINICAL INVESTIGATION
- The relationship between glucocerebrosidase mutations and Parkinson disease
- (2016) Anna Migdalska-Richards et al. JOURNAL OF NEUROCHEMISTRY
- Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance
- (2016) Judith Blanz et al. JOURNAL OF NEUROCHEMISTRY
- Motor and nonmotor heterogeneity of LRRK2 -related and idiopathic Parkinson's disease
- (2016) Connie Marras et al. MOVEMENT DISORDERS
- Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings
- (2016) Charles H. Adler et al. MOVEMENT DISORDERS
- Targeting α-synuclein: Therapeutic options
- (2016) Benjamin Dehay et al. MOVEMENT DISORDERS
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models
- (2016) Simona Petrucci et al. PARKINSONISM & RELATED DISORDERS
- The relationship between essential tremor and Parkinson's disease
- (2016) Mary Ann Thenganatt et al. PARKINSONISM & RELATED DISORDERS
- Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsons disease
- (2016) A. Ghosh et al. Science Translational Medicine
- Nilotinib – Differentiating the Hope from the Hype
- (2016) Richard K. Wyse et al. Journal of Parkinsons Disease
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates
- (2016) Timothy J. Collier et al. Frontiers in Neuroscience
- Vagotomy and subsequent risk of Parkinson's disease
- (2015) Elisabeth Svensson et al. ANNALS OF NEUROLOGY
- Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates
- (2015) Andreas A. Deeg et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Targeting α-synuclein as a therapeutic strategy for Parkinson’s disease
- (2015) Nada B Lawand et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
- (2015) Alevtina D. Zharikov et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
- (2015) Benjamin Dehay et al. LANCET NEUROLOGY
- Development of Passive Immunotherapies for Synucleinopathies
- (2015) Ann-Louise Bergström et al. MOVEMENT DISORDERS
- Active immunization therapies for Parkinson's disease and multiple system atrophy
- (2015) Achim Schneeberger et al. MOVEMENT DISORDERS
- α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
- (2015) W. Peelaerts et al. NATURE
- Spreading of pathology in neurodegenerative diseases: a focus on human studies
- (2015) Johannes Brettschneider et al. NATURE REVIEWS NEUROSCIENCE
- Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle
- (2015) S. Pablo Sardi et al. PROGRESS IN NEUROBIOLOGY
- Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A , tau, and -synuclein
- (2015) M. Goedert SCIENCE
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
- (2014) Johannes Levin et al. ACTA NEUROPATHOLOGICA
- Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
- (2014) Markus Mandler et al. ACTA NEUROPATHOLOGICA
- A Bacteriophage Capsid Protein Provides a General Amyloid Interaction Motif (GAIM) That Binds and Remodels Misfolded Protein Assemblies
- (2014) Rajaraman Krishnan et al. JOURNAL OF MOLECULAR BIOLOGY
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
- (2014) D. Games et al. JOURNAL OF NEUROSCIENCE
- Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s Disease
- (2014) Georgia S. Gaki et al. NEUROMOLECULAR MEDICINE
- Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases
- (2014) S.N. Pchelina et al. NEUROSCIENCE LETTERS
- Genetic Movement Disorders in Patients of Jewish Ancestry
- (2014) Rivka Inzelberg et al. JAMA Neurology
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
- (2013) Michelle S. Beavan et al. ANNALS OF MEDICINE
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance
- (2013) Michaeline L. Hebron et al. Autophagy
- Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models
- (2013) M. L. Hebron et al. HUMAN MOLECULAR GENETICS
- Dangerous duet: LRRK2 and α-synuclein jam at CMA
- (2013) Zhenyu Yue et al. NATURE NEUROSCIENCE
- TFEB-mediated autophagy rescues midbrain dopamine neurons from -synuclein toxicity
- (2013) M. Decressac et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The link between the GBA gene and parkinsonism
- (2012) Ellen Sidransky et al. LANCET NEUROLOGY
- mTOR: on target for novel therapeutic strategies in the nervous system
- (2012) Kenneth Maiese et al. TRENDS IN MOLECULAR MEDICINE
- c-Abl in Neurodegenerative Disease
- (2011) Sarah D. Schlatterer et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
- (2011) S. Z. Imam et al. JOURNAL OF NEUROSCIENCE
- Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
- (2011) Tamar Shachar et al. MOVEMENT DISORDERS
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
- (2010) H. S. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction
- (2009) Thomas G. Beach et al. ACTA NEUROPATHOLOGICA
- Structural Reorganization of α-Synuclein at Low pH Observed by NMR and REMD Simulations
- (2009) Kuen-Phon Wu et al. JOURNAL OF MOLECULAR BIOLOGY
- Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study
- (2009) J Benito-Leon et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in -Synuclein Models of Parkinson's and Lewy Body Diseases
- (2009) B. Spencer et al. JOURNAL OF NEUROSCIENCE
- Genome-wide association study reveals genetic risk underlying Parkinson's disease
- (2009) Javier Simón-Sánchez et al. NATURE GENETICS
- In vivo silencing of alpha-synuclein using naked siRNA
- (2008) Jada Lewis et al. Molecular Neurodegeneration
- Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood
- (2008) Robin Barbour et al. Neurodegenerative Diseases
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search